We are live on ! Find out more
TGI

TRV GP IV Portfolio holdings

AUM $267M
1-Year Est. Return 965.83%
This Fund
S&P 500
This Quarter Est. Return
-41.04%
1 Year Est. Return
+965.83%
3 Year Est. Return
+686.22%
5 Year Est. Return
+581.56%
10 Year Est. Return
AUM
$109M
AUM Growth
-$51M
Cap. Flow
+$39.3M
Cap. Flow %
35.94%
Top 10 Hldgs %
100%
Holding
3
New
1
Increased
Reduced
Closed

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$39.3M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
DNTH icon
1
Dianthus Therapeutics
DNTH
$5.84B
$50.3M 45.98%
500,513
RVMD icon
2
Revolution Medicines
RVMD
$39.9B
$31.1M 28.44%
+1,419,900
New +$39.3M
FULC icon
3
Fulcrum Therapeutics
FULC
$273M
$28M 25.58%
2,343,154

Similar funds

TRV GP IV's Q1 2020 Portfolio in Review

As of Q1 2020, TRV GP IV held 3 positions worth $109M, down 32% from $160M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP IV deployed $39.3M of net new capital in Q1 2020, opening 1 new position. Its largest new stake was Revolution Medicines: 1,419,900 shares worth $31.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP IV's largest Q1 2020 buy was Revolution Medicines: 1,419,900 shares worth $31.1M.
  • TRV GP IV's ten largest holdings make up 100% of its $109M portfolio in Q1 2020.
  • TRV GP IV opened 1 new position and closed 0 in Q1 2020.
  • TRV GP IV's portfolio value fell 32% quarter-over-quarter to $109M.

Based on TRV GP IV's 13F filing for Q1 2020, filed 11 May 2020.